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Abstract
The aims of the guidelines are to help assess the evidence for palliation surgery in patients with cholangiocarcinoma (CCA).
The guidelines are classified in accordance with the location of the primary lesion, i.e. intrahepatic, hilar, and distal. They
are based on comprehensive literature surveys, including results from randomized controlled trials, systematic reviews and
meta-analysis, and cohort, prospective, and retrospective studies. Intrahepatic CCA: resection of lymph-node-positive
tumors and R1/R2 resections have not been shown to provide survival benefit: Evidence levels: 2b, 4; Recommendation
grade C. Hilar CCA: R1 resection is justified as a very efficient palliation: Evidence levels 2b, 4; Recommendations grade B.
Non-surgical biliary stenting is the first choice of palliative biliary drainage: Evidence levels 2b; Recommendation grade B.
Distal CCA: Resection of lymph-node-positive tumors and R1/R2 resections should be performed: Evidence level 4;
Recommendation grade C. Non-surgical stenting is regarded as the first choice of palliation for patients with short life
expectancy. For patients with longer projected survival, surgical bypass should be considered: Evidence levels 1a, 2b, 4;
Recommendation grade B. Palliative resections have a relevant beneficial impact on the outcome of patients with distal and
hilar CCA. Non-surgical stenting is the first choice of palliative biliary drainage for patients with hilar CCA and for those
with distal CCA and short life expectancy. For patients with distal CCA and longer projected survival, surgical bypass
should be considered.
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Introduction
Each location of cholangiocarcinoma (CCA) arising
from the distal extrahepatic duct (DCC), the hilar
bifurcation (HCC), or from the intrahepatic ducts
(ICCs) represents an individual tumor entity with a
different natural history, clinical presentation, and
prognosis. The following guidelines aim to assess the
evidence of palliative surgery in the case of patients
with CCA.
Patients and methods
The guidelines are classified according to the location
of the primary lesion: intrahepatic, hilar, and distal.
They are based on comprehensive literature surveys,
including results from randomized controlled trials,
systematic reviews and meta-analyses, and cohort,
prospective, and retrospective studies. Series with
B10 treated patients were excluded. Evidence levels
and categories for recommendations were assessed in
accordance with the Centre for Evidence-Based
Medicine in Oxford, UK (available at: http://www.
cebm.net) [1].
Intrahepatic cholangiocarcinoma
There are only a few data with a small number of
patients on the role of non-curative resection for
intrahepatic CCA [28]. In only one study with few
patients (n510 patients each group) was a significant
survival benefit seen after palliative resection com-
pared to no resection [2], and in three reports no
survival benefit was seen after non-curative resection
[68].
Jaundice proved to be an independent negative
prognostic factor in the study by Weimann et al. [9],
and no patient with a total bilirubin over 1.2 mg/dl
was found to be resectable in the series by Roayaie
et al. [2]. Long-term survival was reported in only a
few patients after resection of lymph node positive
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tumors [1012]. It is unproved whether R0 resection
of intrahepatic CCA with lymph node metastases,
even in the regional site, provides relevant survival
benefit. Two recent series recommend extended liver
resection with complex vascular and biliary recon-
struction [7] or hepatopancreatoduodenectomy [13]
for patients with advanced intrahepatic CCA, if a
potentially curative resection is possible. A recent
study by Lang et al. [12] shows that there might be
some survival benefit after R1 resection of solitary
intrahepatic CCA compared to R1 resection of multi-
focal tumors.
Recommendation
Resection of lymph-node-positive tumors and R1 and
R2 resections have not been shown to provide survival
benefit and should be performed only in highly
selected patients. An aggressive surgical approach is
justified to achieve complete tumor removal.
Hilar cholangiocarcinoma
The median survival time of patients with non-
resectable hilar CCA is approximately 3 months
without intervention [14] and 410 months with
biliary drainage [12,1421].
Palliative resection
In a study by Seyama et al. [22], no difference in
survival was seen between R0 resection with a margin
B5 mm and R1 resection. Table I indicates that, in
most reports, resection with a histological positive
margin offers survival benefit compared to palliative
treatment [15,16,18,23,24]. The studies by Jarnagin
et al. [25] and Zhang et al. [26] reveal longer survival
after palliative resection compared to no resection
without statistical significance. In a non-randomized
study of 35 patients with hilar CCA, Baton et al.
found that R1 hepatic resection with no other risk
factor can offer long-term survival [27].
Long-term survival has been reported in a few
patients with regional and distant (pM1) lymph node
metastases [15,16,2325,2830]. In the study by
Kitagawa et al., the most important study regarding
the role of lymphadenectomy in hilar CCA, a 5-year
survival rate of 14.7% for patients with regional lymph
node metastases and of 12.3% for those with positive
para-aortic nodes was reported [29].
On the basis of these data, and despite the lack of
prospective randomized trials, R1 resection is an
efficient palliation, and regional lymph node involve-
ment is no contraindication for resection.
Biliary drainage
The palliative surgical options for biliary drainage
include segment III (SgIII) cholangiojejunostomy,
right sectoral duct bypass, and transtumoral tube
placement. The commonly performed operative bili-
ary drainage procedure for hilar CCA is the SgIII
cholangiojejunostomy. Studies concerning SgIII cho-
langiojejunostomy reveal a surgical complication rate
ranging between 17% and 55% and a surgical
mortality from 0% to 17.6% [16,3135]. The re-
ported survival times after SgIII cholangiojejunost-
omy for hilar CCA range between a median survival of
6.3 months and a mean survival of 18.5 months
[15,3135]. Relief of jaundice was achieved in at least
70%.
Table I. Hilar cholangiocarcinoma: survival after palliative resection versus no resection.
Survival (months)
Study Evidence level Palliative resection (n) No resection (n) p
Pichlmayr et al., 1996 [16]
retrospective
2 b R1 resection (n27)
Median: 12.7 mo
Exploratory laparotomy (n99)
5.6 mo
B0.0005
Kosuge et al., 1999 [23]
retrospective
2 b R1 resection (n31) Non-resectional surgery (n24)
Non-surgical procedure (n18)
B0.0001
0.045
Jarnagin et al., 2001 [25]
retrospective
2 b R1 resection (n18)
Median: 21 mo
Exploratory laparotomy (n80)
16 mo
NS
Kawasaki et al., 2003 [15]
retrospective
2 b R1 resection (n25)
Mean: 28 mo
Exploratory laparotomy (n27)
10 mo
B0.0001
Hemming et al., 2005 [18]
prospective database
2 b R1 resection (n11)
Median: 24 mo
Surgical bypass (n14)
12 mo
B0.05
Witzigmann et al., 2006
[24] prospective database
2 b R1 resection (n11)
Median: 12.2 mo
Stenting (n56)
6.4 mo
B0.05
R2 resection (n7)
Median 12.2 mo
StentingPDT (n68)
12 mo
NS
Zhang et al., 2006 [26]
retrospective
2 b Palliative resection (n61)
Median: 10.2 mo
Endoscopic biliary drainage (n21)
6.2 mo
NS
NS, not significant; PDT, photodynamic therapy.
sv .
sv .
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The results of six studies comparing surgical and
non-surgical biliary drainage are given in Table II
[16,23,26,32,35,36]. In these retrospective series, few
patients were included, different techniques were
used, and 3 out of the 6 series were published more
than 10 years ago. In all studies, survival time revealed
no significant difference between surgical and non-
surgical biliary drainage.
Recommendation
All studies are single-arm and single-institution co-
hort studies. The data of these reports were analyzed
retrospectively or were based on prospective data-
bases.
Palliative resection
Resection with microscopic positive margins offers
significant survival benefit over non-resectional treat-
ment. Therefore R1 resection is justified as efficient
palliation. Regional lymph-node involvement should
not be considered as a contraindication for resection if
a complete tumor removal is possible.
Biliary drainage
Because surgical drainage procedures have been
demonstrated not to be superior to non-surgical
palliation with respect to procedure-related mortality
and survival, non-operative biliary stenting is re-
garded as the first choice of palliative biliary drainage.
Surgical bypass should only be re-considered in
patients with a good estimated life expectancy, where
endoscopic and/or percutaneous stenting has failed.
The SgIII cholangiojejunostomy is favoured.
Distal cholangiocarcinoma
Almost all considered data for these guidelines
included patients with malignant distal biliary ob-
struction caused by pancreatic cancer, distal CCA,
and other tumors. In clinical practice, palliative
management of malignant distal biliary obstruction
is not influenced by the underlying histological
diagnosis.
Palliative resection
Only a few data are available concerning palliative
resectioning. Jang et al. reported that 6 out of 49
actual 5-year survivors had either microscopic tumor
disease (n3) or positive lymph nodes (n3) in the
resected specimens [37]. In a study by Murakami
et al., 3 out of 17 lymph-node-positive patients
survived more than 5 years [38]. Lillemoe et al.
showed that, for pancreatic carcinoma, patients with
localized disease who underwent pancreaticoduode-
nectomy with evidence of gross or microscopic diseaseT
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(R1 and R2 resection) have significantly improved
survival compared with similar patients who received
surgical biliary bypass alone [39]. A recent series by
DeOliveira et al. described a survival benefit for
patients with R1/R2 resection compared to non-
resectional palliation [40].
Biliary drainage
No data are available for distal CCA alone. A current
systematic review and meta-analysis of endoscopic
versus surgical bypass results by Moss et al. [41] in
patients with malignant distal biliary obstruction
revealed three prospective randomized trials pub-
lished in the years 1988, 1989, and 1994 [4244];
64% to 86% of the participants in the surgical groups
had pancreatic carcinoma. The majority of surgical
interventions were cholecystojejunostomy or choledo-
choduodenostomy. The results are summarized in
Table III. There was no difference between surgery
and endoscopic plastic stents in rates of technical
success, therapeutic success, survival, and quality of
life. The relative risk of complications was signifi-
cantly reduced in those receiving stents and relative
risk of recurrent biliary obstruction is favored.
Table IV gives the results after palliative surgical
biliary drainage in four other studies. In contrast to
the series of van den Bosch [45] published in 1994,
three newly published studies show low surgical
mortality rates ranging between 0% and 4% after
surgical bypass procedures [4648]. In the study by
Nieveen et al., prolonged survival was seen after
surgical bypass. The Heidelberg group identified
predictors of poor outcome after palliative bypass
surgery, predictors that allow identification of patients
likely to benefit from palliative bypass surgery [48].
Recommendation
Palliative resection
The few data support an aggressive surgical approach
in the presence of regional positive lymph nodes and
even when positive resection margin might result.
Biliary drainage
Considerable advances have taken place in use of the
endoscopic technique and in biliary and pancreatic
surgery. In recent studies, surgical mortality after
palliative biliary bypass has been low. However, it is
likely that results with metal stents will compare more
favorably with surgery than plastic stents when it
comes to recurrent biliary obstruction. At present,
non-surgical stenting is regarded as the first choice of
palliation for patients with short life expectancy.
Patients who, at the time of laparotomy for planned
tumor resection, are found to have unresectable
diseases and concomitant predictors of a favorable T
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Table IV. Malignant distal biliary obstruction: Outcome after palliative surgical and endoscopic biliary drainage.
Diagnosis Technique Mortality Long-term outcome Survival (months)
Author Evidence level Surgical (n) Endoscopic (n) Surgical Endoscopic Surgical Endoscopic Surgical Endoscopic Surgical Endoscopic
Relief of jaundice
van den Bosch et al., 1994
[45]
4 n44 n63 CJ: n34 Plastic stents 13.6% 12.7%[NS] 93.2% 95.2% [NS] Median: 5.5 mo 4.7 mo
retrospective Cancer of pancreatic head or
periampullary region
CD: n5
CCD: n5
Nieveen et al., 2003 [47], 2b n13 n14 HJGJ Wallstent 0% 0% hospital readmission Median: 6.4 mo 3.1 mo
prospective randomized Peripancreatic cancer 64% 64% (p0.05)
Kuhlmann et al., 2007
[46]
2b n269 * HJGJ: n234 * 2.6% * 9 %-read- *
missions related to surgical
bypass
Median: 7.5 mo *
retrospective PC: n227
DCC: n11
Others: n31
HJ: n35
Mu¨ller et al., 2008 [48] 2b n136 * HJGJ: n98 * 4% * * * Median: 8.3 mo *
prospective database PC HJ: n17
GJ: n21
CJ, choledochojejunostomy; CD, choledochoduodenostomy; CCD, cholecystoduodenostomy; PC, pancreatic carcinoma; DCC, distal cholangiocarcinoma; HJ, hepaticojejunostomy;
GJ, gastrojejunostomy.
1
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outcome, and also occasional patients with longer
projected survival, should be considered as candidates
for surgical bypass. Studies, differentiating between
short- and long-term survivors, need to be performed.
Conclusion
Palliative resections have a relevant beneficial impact
on the outcome of patients with distal and hilar CCA.
Non-surgical stenting is the first choice of palliative
biliary drainage for patients with hilar CCA and for
those with distal CCA and short life expectancy. For
patients with distal CCA and longer projected survi-
val, surgical bypass should be considered.
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